Core Insights - The company reported a revenue increase to 830 million yuan in Q1 2025, representing a year-on-year growth of 7.8%, continuing its growth trend [2] - The skincare segment, including brands Galénic, DR.WU, and EVELOM, saw a net income increase of 58%, contributing to a 47.7% growth in skincare revenue, totaling 360 million yuan [2] - The skincare segment accounted for 43.5% of total revenue, maintaining over 30% for 12 consecutive quarters [2] - Gross profit increased by 9.7% year-on-year, with a gross margin rising to 79.1%, marking a historical high for the quarter [2] - The company achieved a Non-GAAP net profit of 7.14 million yuan, marking two consecutive quarters of positive revenue growth and profitability [2] - The company emphasizes R&D as a core strategy for future growth, with Q1 2025 R&D investment nearing 22.64 million yuan, and a cumulative investment of over 580 million yuan since 2020 [2] Market Analysis - Analysts view the Q1 performance as a strong start, with strategic transformation yielding results, laying a solid foundation for stable growth throughout the year [3] - The company projects Q2 2025 total revenue between 810 million and 890 million yuan, indicating a year-on-year growth of approximately 2% to 12% [3] - The board has approved a new stock repurchase plan, allowing for the buyback of up to 30 million USD in common stock over the next 24 months, reflecting management's confidence in the company's long-term prospects [3]